These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 19482477)

  • 1. Enhanced cytotoxicity of a polymer-drug conjugate with triple payload of paclitaxel.
    Erez R; Segal E; Miller K; Satchi-Fainaro R; Shabat D
    Bioorg Med Chem; 2009 Jul; 17(13):4327-35. PubMed ID: 19482477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model.
    Miller K; Eldar-Boock A; Polyak D; Segal E; Benayoun L; Shaked Y; Satchi-Fainaro R
    Mol Pharm; 2011 Aug; 8(4):1052-62. PubMed ID: 21545170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release.
    Etrych T; Sírová M; Starovoytova L; Ríhová B; Ulbrich K
    Mol Pharm; 2010 Aug; 7(4):1015-26. PubMed ID: 20518512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt.
    Duncan R
    Adv Drug Deliv Rev; 2009 Nov; 61(13):1131-48. PubMed ID: 19699249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic.
    Duncan R; Gac-Breton S; Keane R; Musila R; Sat YN; Satchi R; Searle F
    J Control Release; 2001 Jul; 74(1-3):135-46. PubMed ID: 11489490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl)methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage.
    Nakamura H; Etrych T; Chytil P; Ohkubo M; Fang J; Ulbrich K; Maeda H
    J Control Release; 2014 Jan; 174():81-7. PubMed ID: 24269967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate.
    Miller K; Erez R; Segal E; Shabat D; Satchi-Fainaro R
    Angew Chem Int Ed Engl; 2009; 48(16):2949-54. PubMed ID: 19294707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remarkable drug-release enhancement with an elimination-based AB3 self-immolative dendritic amplifier.
    Sagi A; Segal E; Satchi-Fainaro R; Shabat D
    Bioorg Med Chem; 2007 Jun; 15(11):3720-7. PubMed ID: 17416532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymeric nanotheranostics for real-time non-invasive optical imaging of breast cancer progression and drug release.
    Ferber S; Baabur-Cohen H; Blau R; Epshtein Y; Kisin-Finfer E; Redy O; Shabat D; Satchi-Fainaro R
    Cancer Lett; 2014 Sep; 352(1):81-9. PubMed ID: 24614283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HPMA copolymer-cyclic RGD conjugates for tumor targeting.
    Pike DB; Ghandehari H
    Adv Drug Deliv Rev; 2010 Feb; 62(2):167-83. PubMed ID: 19951733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations.
    Lammers T
    Adv Drug Deliv Rev; 2010 Feb; 62(2):203-30. PubMed ID: 19951732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of N-(2-hydroxypropyl) methacrylamide copolymer-Mesochlorine e6 and adriamycin conjugates in combination treatments.
    Shiah JG; Sun Y; Peterson CM; Straight RC; Kopecek J
    Clin Cancer Res; 2000 Mar; 6(3):1008-15. PubMed ID: 10741728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic poly(ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms.
    Clementi C; Miller K; Mero A; Satchi-Fainaro R; Pasut G
    Mol Pharm; 2011 Aug; 8(4):1063-72. PubMed ID: 21608527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-(2-hydroxypropyl)methacrylamide copolymers of a glutathione (GSH)-activated glyoxalase i inhibitor and DNA alkylating agent: synthesis, reaction kinetics with GSH, and in vitro antitumor activities.
    Zheng ZB; Zhu G; Tak H; Joseph E; Eiseman JL; Creighton DJ
    Bioconjug Chem; 2005; 16(3):598-607. PubMed ID: 15898727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Micelles of zinc protoporphyrin conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer for imaging and light-induced antitumor effects in vivo.
    Nakamura H; Liao L; Hitaka Y; Tsukigawa K; Subr V; Fang J; Ulbrich K; Maeda H
    J Control Release; 2013 Feb; 165(3):191-8. PubMed ID: 23220104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implications of N-(2-hydroxypropyl)methacrylamide copolymers.
    Ríhová B; Kubácková K
    Curr Pharm Biotechnol; 2003 Oct; 4(5):311-22. PubMed ID: 14529421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PDEPT: polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-beta-lactamase and HPMA copolymer-C-Dox as a model combination.
    Satchi-Fainaro R; Hailu H; Davies JW; Summerford C; Duncan R
    Bioconjug Chem; 2003; 14(4):797-804. PubMed ID: 12862433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer.
    Chandran SS; Nan A; Rosen DM; Ghandehari H; Denmeade SR
    Mol Cancer Ther; 2007 Nov; 6(11):2928-37. PubMed ID: 18025277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targetable HPMA copolymer-aminohexylgeldanamycin conjugates for prostate cancer therapy.
    Borgman MP; Ray A; Kolhatkar RB; Sausville EA; Burger AM; Ghandehari H
    Pharm Res; 2009 Jun; 26(6):1407-18. PubMed ID: 19225872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Selective tumor-accumulation of HPMA copolymer-mitoxantrone conjugates].
    Huang Y; Zhang ZR
    Yao Xue Xue Bao; 2004 May; 39(5):374-9. PubMed ID: 15338883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.